Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioSpecifics Technologies Corp.

www.biospecifics.com

Latest From BioSpecifics Technologies Corp.

Takeda Paves The Way For Myovant With Phase III Fibroid Success

Takeda has reported the first in a wave of Phase III trials to support the potential uterine fibroid therapy relugolix. The news is good for licensee Myovant, which earlier this year started two larger Phase III studies of the product.

Clinical Trials Companies

BioSpecifics appoints board members

Lynbrook, New York-based BioSpecifics Technologies, a biopharmaceutical company developing first-in-class collagenase-based products, has named two new members to its board of directors: Jennifer Chao and Dr Jyrki Mattila. Ms Chao is an advisory analyst at CoreStrategies Management, a strategic consulting firm she founded in 2008 focused on providing transformational strategy and maximizing corporate valuation. Meanwhile, Dr Mattila is chief business officer of iCeutica. Prior to joining iCeutica in 2013, Dr Mattila was president and CEO of LZ Therapeutics.

Auxilium, BioSpecifics rise on Xiaflex US nod in Peyronie's

The US FDA on 6 December gave its blessing to Auxilium Pharmaceuticals to market its collagenase clostridium histolyticum product Xiaflex as the first and only treatment in the US for Peyronie's disease, a condition in which the penis is curved due to a buildup of scar tissue, causing pain and difficulty during intercourse.

Gynecology & Urology Infectious Diseases

Auxilium’s Peyronie’s Strategy: Start With Few Urologists, Broad Patient Population

Xiaflex is first drug approved for Peyronie’s disease; initial marketing will focus on physicians that already provide invasive treatment.

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Gynecological, Urological
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioSpecifics Technologies Corp.
  • Senior Management
  • J. Kevin Buchi, CEO
  • Contact Info
  • BioSpecifics Technologies Corp.
    Phone: (516) 593-7000
    35 Wilbur St.
    Lynbrook, NY 11563
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register